Introduction {#Sec1}
============

Spinal pain is the most common form of chronic pain \[[@CR1]\], with prevalences of back pain in the general population of 15--45% \[[@CR2]--[@CR4]\], and of 13--22% in the case of cervical pain \[[@CR5]--[@CR7]\]. A neuropathic mechanism is implied in the genesis of this type of pain in 10--19% of all patients with back pain \[[@CR8]--[@CR10]\], resulting in impaired quality of life, and increased utilization of health care resources and economical cost \[[@CR10]--[@CR12]\]. As in other types of chronic pain, patients with back pain not only suffer important comorbidities in the form of other painful disorders \[[@CR10]--[@CR12]\], but frequently also present with prominent sleep disturbances \[[@CR13]\], as well as anxiety and mood disorders \[[@CR14], [@CR15]\].

Despite the introduction of new treatments, the management of patients with neuropathic pain remains a challenge \[[@CR16]\]. In clinical practice, patients with neuropathic pain including those with spinal pain, often receive suboptimal treatment. In this context, the most widely used pharmacological treatments in these patients are nonsteroidal antiinflammatory drugs \[[@CR10]--[@CR12]\], which are scantly effective in the management of pain with a neuropathic component such as the one found in radiculopathies \[[@CR17]\]. Such suboptimal treatment of neuropathic pain contributes substantially to the patient disease burden \[[@CR18]--[@CR20]\]. Although a number of therapies are available for neuropathic pain, including antidepressants, tramadol, opioids, and different antiepileptic drugs, the results of a recent systematic review suggest that, in view of their balance between efficacy and tolerability, gabapentin and pregabalin (PGB) can be regarded as first line treatments for peripheral pain with a neuropathic component \[[@CR16]\]. In addition, these antiepileptic drugs, together with antidepressants, offer the advantage of acting not only on pain but also on the associated symptoms of depression \[[@CR16]\]. The presence of psychological disorders in these subjects may exacerbate pain intensity and disability. Therefore, treatment with anticonvulsive drugs or antidepressants could optimize treatment effectiveness and reduce the occurrence of adverse events \[[@CR21]\].

Pregabalin (PGB) is a structural analog of gamma-aminobutyric acid (GABA) that selectively binds the alpha~2~-delta (α~2~-δ) subunit, of voltage-dependent calcium channels, and which possesses analgesic, anxiolytic, and antiepileptic properties \[[@CR22]\]. In placebo controlled clinical trials, PGB has demonstrated efficacy in ameliorating pain relief and in improving the affective component of pain and sleep disturbances in patients with peripheral diabetic neuropathy \[[@CR23]--[@CR26]\], postherpetic neuralgia \[[@CR27]--[@CR29]\], and spinal cord injury, a model of central neuropathic pain \[[@CR30]\]. However, there is no information on the effect of PGB in patients with cervical or lumbosacral radiculopathy under routine clinical practice ("real world" conditions), these patients representing up to two-thirds of all cases of neuropathic pain in same studies \[[@CR10]\].

The present work was conducted to show evidence from the clinical practice of the effect of PGB upon different Patient-Reported-Outcomes (PROs), representative of the multidimensional nature of these disorders, in a large group of subjects with painful cervical or lumbosacral radiculopathy treated in the primary care setting under conditions of routine clinical practice.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This work presents the results of a secondary analysis of a multicentre, observational (naturalistic) and prospective 12-week study, whose objective was to assess the cost of refractory painful radiculopathy of cervical or lumbosacral origin in Primary Care Settings under real life conditions: the LIRA study \[[@CR31]\]. The study was carried out between September 2005 and April 2006, and involved the participation of 381 primary care physicians randomly selected by quotas according to regional population density in Spain. This was a non-interventional study, and the analgesic treatment administered to the patients was determined by the clinical judgment of the supervising physician. The physician could substitute previous treatment with some other drug, or add a new drug to the existing treatment. In accordance to the Spanish recommendations, the study was approved by the Ethics Committee of Hospital de la Princesa (Madrid), and it was conducted in agreement with the principles contained in the Declaration of Helsinki for studies in humans.

The objective of this secondary analysis was to compare the effect of two patterns of PGB treatment, add-on and monotherapy (PGB add-on and PGB monotherapy groups), when compared with a treatment pattern not including PGB (non-PGB group) on pain alleviation and associated symptoms involving depression, anxiety, sleep, disability and, quality of life.

Study population {#Sec4}
----------------

The original study included patients of both genders aged 18 years or older. The subjects were refractory to previous analgesia and suffered chronic pain with a duration of over 6 months. Refractory was defined as no pain reduction after treatment with at least one course of an analgesic in monotherapy. The pain was secondary to cervical radiculopathy, defined as neck pain irradiating towards the arms, or to lumbosacral radiculopathy, defined as lumbar or sacral pain irradiating to the calves or feet and exhibiting a distribution consistent with involvement of nerve root L5 or S1, respectively. In addition, the patients were required to present a score of ≥4 in the DN4 neuropathic pain diagnostic questionnaire (see below), have a sufficient cultural and educational level to complete health questionnaires written in Spanish, and give their informed consent. This *secondary* analysis only included those patients who met the aforementioned selection criteria, and who had not received treatment with PGB prior to the start of the study.

The study sample size was defined for the primary endpoint of the LIRA study, i.e., the determination of cost and its evolution after 12 weeks of follow-up, under conditions of routine clinical practice in the PCS. Therefore, no sample size predetermination was made for the *secondary* analysis presented in this work.

Clinical evaluations and measurement instruments {#Sec5}
------------------------------------------------

The patients were followed-up for 12 weeks, and were evaluated twice: at baseline and at end of study. At the baseline visit, the clinicians administered the DN4 neuropathic pain diagnostic questionnaire, the selection criteria were checked, and patient sociodemographic data were collected, along with information on the duration of the disease and its treatment, and the use of health care and non-health care resource utilization in the 12 weeks prior to patient inclusion, as reflected in the patient case history. On both the baseline visit and after the 12 weeks of follow-up, the patients were required to complete the Short-Form McGill Pain Questionnaire (SF-MPQ), the Sheehan Disability Inventory (SDI), the Medical Outcomes Study Sleep Scale (MOS), the Hospital Anxiety and Depression Scale (HADS), and the EQ-5D. In addition, the patients kept a diary, with weekly recordings of pain intensity \[visual analog scale (VAS) of the SF-MPQ\] and health status (health status VAS of the EQ-5D).

The DN4 (Douleur Neuropathique 4 questions) neuropathic pain diagnostic questionnaire consists of 10 items that describe different pain characteristics, and allows discrimination of neuropathic pain from non-neuropathic pain. If the patient exhibits a score of at least 4 out of 10 possible points (range 0--10), the patient is considered to have neuropathic pain, with a sensitivity of 83% and a specificity of 90% \[[@CR32]--[@CR34]\].

The main component of the Short-Form McGill Pain Questionnaire (SF-MPQ) comprises 15 descriptors (11 sensory and 4 affective descriptors) that are scored on a scale of 0 = no pain to 3 = severe pain \[[@CR35]\]. The sum of the different intensities in turn yields three pain scores: sensory, affective, and total. The second part of the SF-MPQ consists of a 100-mm VAS for scoring the intensity of the pain experienced by the patient in the previous week. The third part of the instrument is a measure of the intensity of pain at the time of the evaluation, and involves a 6-point scale from 0 = no pain to 5 = unbearable pain.

The Sheehan Disability Inventory (SDI) is a simple and frequently used instrument that evaluates patient functional alteration in three domains: work, social life/leisure, and family life/home responsibilities \[[@CR36]\]. Each domain is scored on an 11-point scale from 0 = no impairment to 10 = extremely impaired. The instrument contains two additional items that explore perceived stress and social support. The former is likewise scored on an 11-point scale, while perceived social support is scored on an 11-point scale expressed as percentages from 0% = no support to 100% = ideal support. The SDI yields three scores: the disability score consisting of the sum of the scores of the first three items, ranging from 0 to 30; the fourth item (perceived stress) score, ranging from 0 to 10; and the fifth item (social support) score, which, unlike the previous four scores, must be inverted.

The Medical Outcomes Study Sleep Scale (MOS) is a self-administered questionnaire that explores key aspects of sleep \[[@CR37]\]. It consists of 12 items distributed into 6 subscales or domains: sleep disturbance, snoring, waking up with shortness of breath or headache, the adequacy of sleep, daytime somnolence, and amount of sleep. In addition, the MOS-sleep provides a summarizing index of sleep problems based on the scores of 9 of its items---the higher the score is, the worse the sleep, except when referring to the dimensions amount of sleep and adequacy of sleep, which are interpreted in the opposite manner. The scale has shown good psychometric properties in patients with neuropathic pain \[[@CR38]\].

The Hospital Anxiety and Depression Scale (HADS) is also a self-administered instrument composed of 14 items, of which 7 explore symptoms of depression and 7 assess anxiety \[[@CR39]\]. Each item is scored from 0 to 3, where 0 = no symptom and 3 = most severe or frequent symptom. The two scores are obtained by adding the 7 items of each subscale---one relating to depression and the other to anxiety (HADS-D and HADS-A)---each score ranging from 0 to 21 points.

The EQ-5D questionnaire evaluates patient-perceived health \[[@CR40]\]. It offers a generic measure of health based on 5 items that explore the degree of alteration in 5 dimensions: mobility, personal care, daily life activities, pain/discomfort, and anxiety/depression. The scores of the 5 items can be used to calculate a utility index that varies from −0.6 to 1.0, where the highest scores correspond to better patient health. The instrument also includes a 20-cm visual analog scale (EQ-5D VAS) ranging from 0 = worst imaginable health status to 100 = best imaginable health status.

As the original study was designed as an observational epidemiological research, forced adverse events reporting (i.e.: type of adverse event, seriousness, etc.) could not be implemented except to document the reason for discontinuation before the end of study visit.

Statistical analysis {#Sec6}
--------------------

For the statistical analysis of this secondary evaluation, and according to the treatment prescribed from the baseline visit as established by clinical judgment, the patients were divided into three groups: patients that substituted or added another drug other than PGB to previous treatment (Non-PGB group); patients that substituted previous treatment with PGB as monotherapy (PGB monotherapy group); and patients that received PGB added onto the existing therapeutic regimen (PGB add-on group).

The baseline characteristics of the patients are reported as the mean and standard deviation for quantitative variables, while qualitative variables are represented as absolute and relative frequencies. Normality distribution assumptions were verified using the Kolmogorov--Smirnov test. Analysis of variance (ANOVA), the Kruskal--Wallis test, and the chi-square test were used to assess the baseline homogeneity of the variables in the three study groups.

The proportion of patients with a reduction of at least 50% in pain intensity as rated by the SF-MPQ pain VAS was calculated and defined as responders. The cumulative number of days without pain or with mild pain was calculated (\<40 mm on the VAS of the SF-MPQ). In addition, the changes in the above mentioned scales and subscales versus baseline were used as assessment variables. The comparison between groups of the changes in quantitative variables versus baseline was carried out by analysis of covariance (ANCOVA), adjusting for the baseline score on each corresponding scale and the number of previous drugs. In turn, the changes in ordinal qualitative variables versus baseline were evaluated by means of a logistic regression model, adjusting for the baseline score and the number of previous drugs. These analyses were made in application to the included patients that completed the 12 weeks of follow-up, and for whom changes in the baseline variables could be calculated. The statistical significance of the comparisons between treatments groups was adjusted by means of the Tukey multiple comparisons method. All statistical tests were two-sided, and statistical significance was considered for *P* \< 0.05.

With the purpose of evaluating the clinical significance of the changes in the different measurements, a calculation was made of the effect size obtained, based on the difference between the means of a given measurement before and after treatment, divided by the corresponding standard deviation measured before treatment \[[@CR41]\]. Interpretation of the effect size was based on the established criterion which considers an effect size of 0.20 to \<0.50 as small; a size of ≥0.50 and \<0.80 as moderate; and a size of ≥0.80 as large \[[@CR41]\].

Based on the weekly patient scores corresponding to the VAS of the EQ-5D, calculations were made of the gains in QALYs (quality-adjusted life years) after 12 weeks of follow-up. The direct VAS score divided by 100 was used as an estimator of utility value (in metric terms 0--1, where 0 = death and 1 = perfect health), from which the gain in QALYs was calculated. Trapezoidal approximation was used for this calculation, employing the baseline and weekly utility values as reference values \[[@CR42]\].

Results {#Sec7}
=======

Patient distribution {#Sec8}
--------------------

A total of 1,879 patients were included in the LIRA study, of which 1,351 had not been previously exposed to PGB and met the inclusion/exclusion criteria for this *secondary* analysis. The analysis was finally performed in 1,304 patients (96.5%) that completed the 12 weeks of the study. Figure [1](#Fig1){ref-type="fig"} reports these data, along with the causes of patient losses to follow-up. Radiculopathy was of lumbar origin in 86.9% of cases, and of cervical origin in 13.1% (without significant differences in this distribution according to treatment group).Fig. 1Patient disposition

Baseline demographic and clinical characteristics {#Sec9}
-------------------------------------------------

The recruited population was of middle age, with a female predominance, and over half of the subjects were without working activity (Table [1](#Tab1){ref-type="table"}). On average, patients had painful radiculopathy for 2 years and were treated with at least one curse of an analgesic. The most frequent previous treatments were analgesics, particularly nonsteroidal antiinflammatory drugs (NSAIDs), and paracetamol, which were used by at least 60% and almost 50% of the subjects, respectively. Frequency of previous drug use was numerically different between groups. However, except for vitamin use (more frequently used by PGB add-on group, *P* \< 0.001), differences in the others type of drug were hardly statistically significant (Table [1](#Tab1){ref-type="table"}). The three treatment groups were similar in terms of demographics characteristics, with the exception of fewer previous treatments in the PGB monotherapy group versus the other two groups (Table [1](#Tab1){ref-type="table"}). The patients in the PGB add-on group generally presented with poorer clinical conditions, with increased pain intensity, worst social and working activity, and poorer quality of life (Table [2](#Tab2){ref-type="table"}). Although of questionable clinical relevance, anxiety levels were significantly greater in the PGB add-on group than in the other two groups (Table [2](#Tab2){ref-type="table"}). There were no differences with regard to sleep disturbances.Table 1Demographic and clinical characteristicsCharacteristicsNon-PGB (*N* = 155)^a^PGB monotherapy (*N* = 473)^a^PGB add-on (*N* = 676)^a^*P*Sex (female), *n* (%)90 (57.8)262 (55.3)377 (55.8)0.879Age (years), mean (SD)56.3 (13.2)56.0 (12.7)57.2 (12.1)0.230Body mass index (kg/m^2^)27.9 (4.2)27.3 (3.8)27.5 (3.8)0.204Marital status (married or with couple), *n* (%)120 (77.2%)342 (72.3%)498 (73.6%)0.525Labor status, *n* (%)0.149 Active43 (27.9)111 (23.3)178 (26.3) Housewife26 (16.9)70 (14.7)114 (16.8) Sick leave21 (13.6)44 (9.1)98 (14.5) Unemployed9 (5.8)18 (3.7)26 (3.7) Retired46 (29.9)199 (42.1)231 (34.1) Unknown9 (5.8)33 (7.0)30 (4.5)Duration (years), mean (SD)2.1 (3.7)2.1 (4.1)1.9 (3.4)0.117No. previous treatments, mean (SD)2.8 (1.7)2.2 (1.3)2.7 (1.4)\<0.001Previous treatments^b^, *n* (%) NSAID104 (67.1)294 (62.2)460 (68.1)0.039 Paracetamol75 (48.4)207 (43.7)317 (46.9)0.442 Metamizol41 (26.4)96 (20.2)134 (19.8)0.174 Opioids63 (40.6)136 (28.8)219 (32.4)0.022 Antiepileptic drug16 (10.1)48 (10.2)49 (7.3)0.173 Tricyclic antidepressants14 (8.8)24 (5.1)59 (8.8)0.049 Benzodiazepines21 (13.5)78 (16.5)137 (20.2)0.077 Vitamins (B6,B12)17 (11.0)25 (5.3)88 (13.1)\<0.001 Others^c^10 (6.4)19 (4.0)78 (11.5)\<0.001*NSAID* Nonsteroidal antiinflammatory drug, *SD* standard deviation, *AED* antiepileptic drug, *NPP* neuropathic pain, *PGB* pregabalin;^a^Total number of patients analyzed; some subjects failed to report the data relating to certain variables^b^The patients could have received more than one previous treatment^c^Includes lidocaine, corticoidsTable 2Baseline visit patient-reported health outcomesHealth outcomeNon-PGB (*N* = 155)^a^PGB monotherapy (*N* = 473)^a^PGB add-on (*N* = 676)^a^*P*SF-MPQ, mean (SD) Sensory15.5 (5.8)15.1 (6.0)16.0 (6.0)0.045 Affective4.8 (3.3)4.4 (3.2)5.0 (3.2)0.012 Total20.3 (8.4)19.5 (8.4)21.0 (8.5)0.016 PPI (0--5)2.7 (0.8)2.7 (0.8)2.8 (0.8)0.014 VAS (0--100)71.4 (15.3)70.4 (14.6)72.7 (15.3)0.032MOS-sleep, mean (SD) Summary index (0--100)47.6 (16.9)46.2 (17.2)48.4 (17.2)0.096 Sleep disturbance (0--100)50.6 (20.1)48.5 (19.5)51.96 (19.6)0.015 Snoring (0--100)39.3 (30.6)37.3 (28.6)37.4 (28.6)0.754 Shortness of breath (0--100)30.1 (25.4)29.5 (26.6)31.3 (26.0)0.539 Sleep quantity, hours5.8 (1.5)5.8 (1.4)5.6 (1.3)0.004Adequacy of sleep (100--0)39.1 (23.6)40.0 (23.1)36.8 (23.2)0.067Daytime somnolence (0--100)40.2 (19.4)38.1 (19.0)37.5 (19.0)0.230HADS, mean (SD) Depression (0--21)10.8 (4.5)10.0 (4.5)10.7 (4.4)0.014Anxiety (0--21)10.5 (3.9)9.9 (3.9)10.6 (3.8)0.022SDI, mean (SD) Disability (0--30)^b^18.9 (6.0)18.4 (5.8)20.0 (5.4)\<0.001 Perceived stress (0--100)6.0 (2.1)5.9 (2.1)6.3 (1.9)0.007Perceived social support, % (0--100)58.1 (22.3)56.0 (22.4)57.4 (23.6)0.503EQ-5D VAS, mean (SD) (0--100)42.3 (17.2)42.5 (18.2)38.9 (17.5)0.002 Mobility^c^, *n* (%)53 (34.9)134 (28.9)181 (27.0)0.051 Personal care^c^, *n* (%)59 (38.8)203 (43.8)264 (39.5)0.156 Daily life activities^c^, *n* (%)21 (13.8)51 (11.1)47 (7.0)\<0.001 Without pain, *n* (%)5 (3.3)11 (2.4)8 (1.2)0.002 Without anxiety/depression, *n* (%)37 (24.5)127 (27.4)150 (22.5)0.010*SD* Standard deviation, *VAS* visual analog scale, *HADS* Hospital Anxiety Depression Scale, *MOS* Medical Outcomes Study, *PGB* pregabalin, *PPI* present pain intensity, *SDI* Sheehan Disability Inventory, *SF-MPQ* Short Form McGill Pain Questionnaire^a^Total number of patients analyzed; some subjects failed to report the data relating to certain variables^b^Sum of the scores of the three disability items^c^Patients responding without problems in the item

Drug therapy during study {#Sec10}
-------------------------

Most of the patients in the non-PGB group (67%) received two or more drugs for pain treatment \[mean (SD): 2.2 (1.4)\], the most frequent being paracetamol (37%, mean dose ± standard deviation: 2.144 ± 1.010 mg/day), metamizol (21%, 1,087 ± 455), tramadol (19%, 157 ± 60 mg/day), ibuprofen (17%, 1.094 ± 451 mg/day), diclofenac (16%, 88 ± 49), gabapentin (13%, 989 ± 594 mg/day), tetrazepam (8%, 65 ± 24 mg/day), diazepam (6%, 6 ± 3 mg/day), fentanil (6%, 59 ± 23 mg/day), codeine (6%, 59 ± 23 mg/day), and amitriptyline (5%, 38 ± 28 mg/day). In the PGB monotherapy group, the mean dose was 187 ± 106 mg/day. The most frequently used drugs in the PGB add-on group (mean dose: 191 ± 107 mg/day) were paracetamol (42%, 2.146 ± 1.077 mg/day), ibuprofen (21%, 1.218 ± 555 mg/day), tramadol (20%, 163 ± 81 mg/day), diclofenac (13%, 126 ± 52), metamizol (11%, 1.517 ± 863 mg/day), tetrazepam (7%, 80 ± 42 mg/day), diazepam (6%, mean dose 7 ± 4 mg/day), amitriptyline (5%, 28 ± 20 mg/day), and fentanil (3%, mean dose 48 ± 23 mg/day). The mean number of drugs during the study in this group was 2.8 (1.1).

Patient-Reported-Outcomes (PROs) {#Sec11}
--------------------------------

### Pain reduction {#Sec12}

The three groups showed significant and clinically relevant reductions in pain severity after 12 weeks of follow-up (Table [3](#Tab3){ref-type="table"}). Pain reduction proved significantly greater in the groups administered PGB, with changes of 56 and 51%, respectively, for PGB as monotherapy and add-on treatment, versus 36% in the patients who did not receive PGB (*P* \< 0.0001, Table [3](#Tab3){ref-type="table"}). The differences in pain reduction were significant from the fourth week, and maintained until the end of the study (Fig. [2](#Fig2){ref-type="fig"})---resulting in an increased cumulative number of days with no/mild pain (\<40 mm on the VAS of the SF-MPQ) in the groups administered PGB versus the patients without PGB (*P* \< 0.0001, Table [3](#Tab3){ref-type="table"}). At the end of the study, 63 and 56% of the patients administered PGB as monotherapy and on an add-on basis, respectively, showed a 50% reduction in pain intensity (responders), versus 33% in the non-PGB group (*P* \< 0.0001, Table [3](#Tab3){ref-type="table"}).Table 3Mean and magnitude of change (effect size) of the different pain parameters measured by the SF-MPQ according to treatment groupHealth outcomeNon-PGB (*N* = 155)^a^PGB monotherapy (*N* = 473)^a^PGB add-on (*N* = 676)^a^*P*SF-MPQ Sensory−5.1 (5.6) \[0.88\]−8.3 (6.3) \[1.38\]−8.0 (5.9) \[1.33\]\<0.001 Affective−2.2 (2.7) \[0.66\]−2.9 (3.0) \[0.91\]−3.0 (2.9) \[0.94\]\<0.001 Total−7.4 (7.6) \[0.88\]−11.2 (8.5) \[1.33\]−11.0 (8.0) \[1.29\]\<0.001 PPI−0.9 (1.0) \[1.13\]−1.5 (1.0) \[1.88\]−1.4 (1.0) \[1.75\]\<0.001SF-MPQ intensity (VAS) mm−25.0 (22.0) \[1.63\]−40.1 (23.2) \[2.75\]−37.1 (24.0) \[2.42\]\<0.001 %35.6 (27.8)56.4 (27.6)50.7 (27.4)\<0.001Responders (%)^b^32.962.856.3\<0.001Cumulative days without pain or mild pain (VAS \<40 mm)20.2 (26.9)36.3 (29.7)30.7 (28.9)\<0.001Values given as mean (standard deviation) \[effect size\]*VAS* Visual analog scale, *PGB* pregabalin, *PPI* present pain intensity, *SF-MPQ* Short Form McGill Pain Questionnaire^a^Total number of patients analyzed; some subjects failed to report the data relating to certain variables^b^Responders: patients with a reduction of at least 50% in pain intensity as scored by the VAS of the SF-MPQFig. 2Mean weekly change in pain intensity as scored by the VAS of the SF-MPQ

### Other Patient-Reported-Outcomes measurements {#Sec13}

Improvements in comorbid conditions including sleep disturbances, depression, and anxiety were significantly superior in the patients administered PGB, with clinically relevant improvement (large effect size) while the changes in the non-PGB group were only moderate (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). The effect upon sleep showed a similar pattern for the six dimensions of the MOS-sleep scale, though none of the treatment groups showed relevant changes in the dimensions "snoring" or "waking up with shortness of breath or headache" (Table [5](#Tab5){ref-type="table"}). On the other hand, with the exception of "sleep disturbance", which exhibited a moderate effect size, the changes in the non-PGB group for all the MOS-Sleep dimensions were small. In contrast, the PGB-treated groups showed large changes for "sleep disturbance" and "adequacy of sleep", with moderate changes for "amount of sleep" and "daytime somnolence" (Table [5](#Tab5){ref-type="table"}).Table 4Mean and magnitude of change (effect size) of the patient reported health outcomes at the end of the study, according to treatment groupHealth outcomeNon-PGB (*N* = 155)^a^PGB monotherapy (*N* = 473)^a^PGB add-on (*N* = 676)^a^*P*HADS Depression (0--21)−2.5 (4.0) \[0.55\]−3.9 (4.3) \[0.87\]−3.8 (4.2) \[0.86\]\<0.001 Anxiety (0--21)−2.2 (3.4) \[0.56\]−3.8 (4.0) \[0.97\]−3.6 (3.6) \[0.95\]\<0.001SDI Disability (0--30)^b^−5.7 (5.9) \[0.95\]−9.2 (6.5) \[1.59\]−8.9 (6.3) \[1.65\]\<0.001 Perceived stress (0--100)−1.8 (2.1) \[0.86\]−3.0 (2.3) \[1.43\]−2.8 (2.2) \[1.47\]\<0.001 Perceived social support, % (0--100)−1.4 (1.8) \[0.06\]−2.4 (2.4) \[0.11\]−1.2 (1.9) \[0.05\]0.004EQ-5D VAS (0--100)18.6 (22.3) \[1.08\]29.2 (22.2) \[1.60\]29.5 (21.2) \[1.69\]\<0.001 Mobility^c^, *n* (%)77 (50.7)303 (65.3)410 (61.1)\<0.001 Personal care^c^, *n* (%)90 (59.2)360 (77.6)487 (72.9)\<0.001 Daily life activities^c^, *n* (%)50 (32.9)252 (54.7)306 (45.7)\<0.001 Without pain, *n* (%)26 (17.1)165 (35.7)160 (23.9)\<0.001 Without anxiety/depression, *n* (%)74 (49.0)302 (65.1)388 (58.3)0.002QALYs gained0.0284 (0.0409)0.0407 (0.0389)0.0427 (0.0369)\<0.001Values given as mean (standard deviation) \[effect size\]*VAS* Visual analog scale, *HADS* Hospital Anxiety Depression Scale, *MOS* Medical Outcomes Study, *PGB* pregabalin, *SDI* Sheehan Disability Inventory, *QALY* Quality-adjusted life year^a^Total number of patients analyzed; some subjects failed to report the data relating to certain variables^b^Sum of the scores of the first three items^c^Patients responding without problems in the itemTable 5Mean and magnitude of change (effect size) of the different dimensions of sleep measured by the MOS-sleep, according to treatment groupDimension of the MOS-sleepNon-PGB (*N* = 155)^a^PGB monotherapy (*N* = 473)^a^PGB add-on (*N* = 676)^a^*P*Summary index (0--100)−9.3 (16.0) \[0.55\]−17.3 (18.1) \[1.01\]−17.3 (18.1) \[1.01\]\<0.001Sleep disturbance (0--100)−11.2 (18.5) \[0.56\]−19.3 (20.1) \[0.99\]−20.0 (19.8) \[1.02\]\<0.001Snoring (0--100)0.9 (23.2) \[0.03\]−5.5 (23.6) \[0.19\]−5.1 (20.8) \[0.18\]0.001Shortness of breath (0--100)−2.1 (27.0) \[0.08\]−10.7 (23.8) \[0.40\]−12.3 (24.7) \[0.47\]\<0.001Sleep quantity, hours+0.4 (1.2) \[0.27\]+0.9 (1.3) \[0.64\]+1.0 (1.2) \[0.77\]\<0.001Adequacy of sleep (100--0)+11.3 (21.5) \[0.48\]+21.2 (25.3) \[0.92\]+20.7 (24.3) \[0.89\]\<0.001Daytime somnolence (0--100)−5.6 (18.9) \[0.29\]−10.9 (19.6) \[0.57\]−9.5 (19.6) \[0.50\]\<0.001Values given as mean (standard deviation) \[effect size\]*MOS* Medical Outcomes Study, *PGB* pregabalin^a^Total number of patients analyzed; some subjects failed to report the data relating to certain variables

All treatment groups showed relevant improvement in the impact of painful radiculopathy on patient perceived stress and social and working activities as measured by the SDI (Table [4](#Tab4){ref-type="table"}). Once again, these changes were significantly greater in the two groups that received PGB. General patient health according to the EQ-5D VAS also improved significantly more in the PGB-treated groups, and the clinical impact was likewise greater as measured by the effect size (Table [4](#Tab4){ref-type="table"}), in turn giving rise to a greater gain in QALYs in the groups exposed to PGB (Table [4](#Tab4){ref-type="table"}). These differences were seen to be significant from week 5 of the study, and maintained until week 12 (Fig. [3](#Fig3){ref-type="fig"}). In general terms, the benefit observed in each of the five dimensions of the EQ-5D was significantly greater in the groups treated with PGB, particularly among those patients that received the drug as monotherapy (Table [4](#Tab4){ref-type="table"}).Fig. 3Mean weekly change in health status as scored by the VAS of the EQ-5D

Discussion {#Sec14}
==========

Few randomized clinical trials have been run in patients presenting with pain with a neuropathic component secondary to radiculopathy, and particularly in general in chronic pain of mixed origin \[[@CR16]\]. In addition, very few current trials address the pharmacological management of these clinical conditions. Our data appear to be the first involving PGB for the management of cervical and lumbosacral radiculopathy under conditions of routine clinical practice in the primary care setting. Our findings suggest that PGB is effective under "Real World" conditions for treating pain of this kind and also for ensuring clinically relevant improvement in the associated symptoms of anxiety, depression, and sleep disturbances---with amelioration of patient disability and improvement in quality of life.

Monotherapy with PGB, or as an add-on therapy, produced a very marked decrease in pain (over 50%), with a large effect size. The proportion of responders, 63% and 56% in the monotherapy and add-on groups, respectively, was at least similar to that recorded in clinical trials of PGB among patients with diabetic neuropathy (39 and 48%) \[[@CR23]--[@CR25]\], postherpetic neuralgia (28--50%) \[[@CR27]--[@CR29]\], and superior to the proportion observed in patients with central neuropathic pain associated with spinal cord injury (22%) \[[@CR30]\]. The apparent analgesic superiority versus the subjects that did not receive PGB proved consistent across all outcome measures, with large effect sizes for the most part, and likewise superior to those seen in the non-PGB patients. These data point to the broad activity spectrum of PGB in application to pain with a neuropathic component. Although always difficult to interpret in the context of an observational study, it cannot be ruled out that this apparent superiority may be due in part to inadequate management of patients belonging to the non-PGB group. In a large percentage of cases, these latter patients were treated with NSAIDs (67%) or paracetamol (37%). While these drugs have an effect upon the somatic component of pain, they have not been shown to be effective in the management of neuropathic pain. In contrast, only 13% of the patients received gabapentin, amitriptyline in 5%, and 25% received opioids. This situation is almost analogous to that described in other countries such as the United Kingdom or Spain, likewise in the primary care setting, where NSAIDs are widely used for the treatment of mixed presentations (65%), while the use of drugs of proven clinical efficacy in the treatment of neuropathic pain, such as antiepileptic agents or tricyclic antidepressants, is more limited (10 and 3%, respectively) \[[@CR43], [@CR44]\].

The effect of PGB on comorbid symptoms of sleep disturbances, depression, and anxiety, was significantly superior in the patients administered PGB, with large effect sizes, versus the moderate changes seen in the non-PGB group. Given the frequent co-occurrence of these comorbidities in such patients \[[@CR21]\], the role of PGB proves particularly useful in such situations. While opiods have been shown to be effective in reducing neuropathic pain \[[@CR16]\], their beneficial effects upon patient mood, disability, and quality of life are not consistent \[[@CR45], [@CR46]\]. In addition, the beneficial effect of PGB on treating comorbid conditions could reduce health care resource utilization and costs. As an example, it has been reported that in patients with back pain, existing physical and mental comorbidities, led to a significant increase in health care costs \[[@CR47]\]. Globally, the superior effectiveness of PGB in ameliorating pain, and its greater effect upon associated comorbidities, could explain the improvement we recorded in relation to social and working incapacitation and quality of life, compared with the patients administered other treatments.

The mean PGB dose used in our study, about 190 mg/day, lies within the effective dosing range for neuropathic pain (150--600 mg/day), and perhaps is at the lower limit when compared with the doses used in clinical trials with PGB. Most of the PGB trials mentioned above made use of a fixed-dose scheme; comparisons with our study are therefore difficult to establish. However, in a randomized clinical study of PGB versus placebo in patients with neuropathic pain associated to peripheral diabetic neuropathy or postherpetic neuropathy, in which a flexible dosing scheme was used, the mean dose was almost double what we observed in routine practice (372 mg/day) \[[@CR26]\]. Whether lower doses are needed in clinical practice, or whether simple underdosing is involved, is a question which our study was unable to answer. However, underdosing seems more likely, since the prescription of doses lower than those recommended for pain, including pain of neuropathic origin, is often reported in the literature \[[@CR20], [@CR43]\].

Despite the lack of evidence from randomized clinical trials, it is common in clinical practice to use combinations of several drugs to treat pain with a neuropathic component \[[@CR48]--[@CR51]\]. In our analysis, the PGB add-on treatment group yielded superior results compared with patients administered other treatments, and with the exception of pain, these results were moreover analogous to those obtained with PGB in monotherapy. While statistically significant, the differences observed in pain management with PGB as monotherapy compared with the PGB add-on group are of scant clinical relevance for a number of reasons: the patients in the PGB add-on group generally presented with more severe symptoms; the differences in effect size between the two PGB-treated groups were not large; and the impact upon patient disability and quality of life was similar in both groups.

Our study provides data on the effectiveness of adding PGB to existing analgesic treatment. Nevertheless, it would be worthwhile to conduct controlled clinical trials to evaluate the possibility that PGB combined with an analgesic could be superior to the drugs in monotherapy for the management of painful radiculopathy of mixed origin. There is some evidence to suggest that this may be the case. Some analgesics such as paracetamol or the NSAIDs are ineffective in application to pure neuropathic pain condition, but may be of help in the presence of a nociceptive component. On the other hand, a randomized and placebo controlled trial involving the combination of pregabalin and an NSAID has shown better performance than the drugs in monotherapy, as preoperative analgesia in vertebral fusion surgery \[[@CR52]\].

Our study, however, has some limitations that must be taken into account. Because of its observational nature, it is exposed to bias and confounding factors. The impact of such bias, particularly selection bias, is difficult to establish. However, at least in the PGB add-on treatment group, such bias probably acts against the drug, since these were more seriously affected patients. On the other hand, the logical open-label design may have overestimated the effect of treatment. Another limitation of our study is represented by the fact that the study did not specifically assess the effect of pharmacological intervention, hence we have no systematic evaluation of the tolerability of the treatments. However, the high proportion of patients that completed the treatment in all the groups analyzed, and the low incidence of drop-outs attributable to adverse effects, suggest that the three treatment strategies were very well tolerated. Last, it is worthy to comment on the diagnosis of radiculopathy in the study. While patients were identified using ICD-10 classification criteria for radiculopathies in conjunction with a diagnostic tool administered to assist general practitioners in categorizing the neuropathic component of pain, we cannot exclude the possibility of misdiagnosis to some extent.

Conclusions {#Sec15}
===========

Overall, in spite of these limitations, the results of this analysis complement the findings observed with PGB in clinical trials, then consolidating PGB as an effective therapy for the treatment of the neuropathic component of pain in subjects with cervical or lumbosacral radiculopathy in real world conditions of care. This effectiveness resulted in a reduction of the associated symptoms of pain in routine medical practice, leading to lower disability and better quality of life of patients. To conclude, our analysis suggests that in routine clinical practice, pregabalin both as monotherapy and in combination, is associated with considerable pain reduction, and important improvement in associated symptoms such as sleep, affective disorders, and anxiety. In addition, PGB treatment reduces associated disability and improves the health condition of patients with neuropathic pain associated with cervical or lumbosacral radiculopathy. The possible superiority of this drug over other treatments, the usefulness of pregabalin doses higher than those used in this analysis, and the potential utility of combining the drug with other treatments for the management of this type of neuropathic pain are aspects that should be further examined in the context of randomized clinical trials.
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